Company intelligence / Profile preview

Transformative Biotech

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Transformative Biotech’s direct-to-PCR technology, which does not require a separate extraction step, has been proven in high-volume commercial clinical use (e.g., over 600,000 tests for SARS-CoV-2). It significantly reduces turnaround time and cost, and enables molecular testing in various settings, including at-home and point-of-care. The technology offers quantitative as well as qualitative (positive/negative) results for pathogen detection and has been widely validated in clinical diagnostics for infectious diseases and is expanding into cancer diagnostics[5][7][9].

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceMolecular diagnostic
Industry: Molecular Diagnostics

Partnerships

Summit Biolabs (technology asset acquisition)[7]

Beyond the preview

Go deeper on Transformative Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transformative Biotech.

Explore the full profile